Company Filing History:
Years Active: 2011
Title: Hendrik Jan Guchelaar: Innovator in Pharmacogenetics
Introduction
Hendrik Jan Guchelaar is a notable inventor based in AB Gouda, Netherlands. He has made significant contributions to the field of pharmacogenetics, particularly in the prediction of treatment efficacy for patients with recent-onset arthritis. His work is crucial for improving patient outcomes through personalized medicine.
Latest Patents
Guchelaar holds a patent for a pharmacogenetic method aimed at predicting the efficacy of methotrexate monotherapy in patients with recent-onset arthritis. The patent details methods for determining responsiveness to antifolate therapy by correlating clinical parameter values with predefined responsiveness values. This innovative approach considers various factors, including polymorphisms in the methylenetetrahydrofolate dehydrogenase (MTHFD1) gene, the presence of rheumatoid factors, and patient demographics such as gender and smoking status. He has 1 patent to his name.
Career Highlights
Hendrik Jan Guchelaar is associated with Exagen Diagnostics, Inc., where he continues to advance research in pharmacogenetics. His work focuses on enhancing the understanding of how genetic factors influence treatment responses, which is vital for developing effective therapeutic strategies.
Collaborations
One of his notable collaborators is Tom Willem Johannes Huizinga, with whom he has worked on various projects related to pharmacogenetics and arthritis treatment.
Conclusion
Hendrik Jan Guchelaar's contributions to pharmacogenetics represent a significant advancement in personalized medicine, particularly for patients with arthritis. His innovative methods have the potential to transform treatment approaches and improve patient care.